As early as 2000,
U.S. health authorities raised concerns about the French breast implant
maker at the heart of a scandal affecting hundreds of thousands of
women worldwide. That was almost ten years before the company came under
scrutiny from European regulators.
The Food and Drug
Administration sent an investigator to inspect a plant run by the
manufacturer, Poly Implant Prothese (PIP), at La Seyne Sur Mer in
southeastern France in May 2000. Shortly afterwards, the FDA sent the company's founder,
Jean-Claude Mas, a warning letter saying the implants were "adulterated"
and citing at least 11 deviations from good manufacturing practices.
The
problems had to do with PIP's saline implants, a different line from
the silicone implants that French authorities ordered off the market in
2010 for using industrial-grade silicone instead of medical-grade
silicone, leading to the French firm's bankruptcy. Still, the plant
inspected by the FDA was used to manufacture the silicone implants for
PIP.
The French government last
week recommended that women in France who have PIP's silicone gel-filled
implants get them removed by their surgeons after the implants appeared
to have an unusually high rupture rate. Other countries, including
Britain and Brazil, said women should visit their surgeons for checks.
A
critical question is why the FDA's warning didn't trigger greater
scrutiny of PIP's activities by regulators in France and elsewhere.
Officials at the FDA and France's health regulator were not available
for comment on Monday on whether the FDA shared information about its
inspection of the PIP plant, though the warning letter was made public
in 2000.
Poor health
No one has been charged in the case.
Sources said a Marseilles court could soon announce fraud charges against four to six ex-PIP employees.
There
is also an investigation into involuntary homicide by French
authorities, following the death from cancer of a woman last year. She
had received PIP implants. The French government has not presented any
evidence of an increased cancer risk from the product.
Mas'
lawyer Yves Haddad told Reuters on Monday that his 72-year-old client
is in poor health but ready to respond to any court summons. Haddad
denied that Mas was in hiding, reiterating that he was still in southern
France's Var region.
"He's
currently in very bad health because he has just undergone a difficult
surgery that prevents him from walking," Haddad said. "He is worried by
the importance this matter is taking on. He is angry at those who
pointlessly add to people's suffering," the lawyer added.
Reuters didn't subsequently reach him to ask about the FDA's findings.
The
U.S. concerns about PIP's saline implants more than 11 years ago could
mean that there are safety issues for more women than the 300,000
worldwide who received the company's silicone implants. The number of
women with PIP saline implants worldwide and the safety record of the
device could not be immediately verified.
The
FDA's letter was cited in a lawsuit filed in the U.S. District Court
for the Southern District of Texas on behalf of U.S. patients who
received the saline implants in the late 1990s, and one who received
them as recently as 2001. The plaintiffs said that the implants deflated
several years later.
Deflation
can be a problem with breast implants. The key issue is whether the
incidence suffered by a particular product is higher than health
authorities deem to be acceptable.
The
FDA's letter is available on the agency's website. Reuters could not
ascertain the outcome of the lawsuit, and the lead lawyer, Charles
Houssiere, could not be reached for comment.
The
FDA's warning letter, dated June 22, 2000, cited PIP's failure to
investigate the deflation of its saline implants and a failure to report
more than 120 complaints in France and elsewhere to the FDA. The letter
said the plant also did not have a process in place to make sure the
implants it produced met design specifications.
No formal approval
PIP
began selling its saline implants in the United States in September
1996, under a 510(k) accelerated review application that did not require
the company to submit clinical trials to show an implant's safety and
effectiveness, as long as it was "substantially equivalent" to devices
already on the market.
The French
company could not sell its silicone-gel implants in the United States at
the time because the FDA had prohibited the sale of all such implants
from 1992 until 2006 for most women because of safety concerns.
However,
for many years, the FDA allowed manufacturers to sell saline implants
without formal safety trials, because many were sold before the agency
received the authority to regulate medical devices. The agency assumed
they were safe unless proven otherwise.
In
2000, due to concerns about possible complications such as infections
and rupturing, the agency finally required all implant companies to
submit a formal application, known as pre-market approval, to continue
selling their products.
PIP was one
of three companies that submitted an application, which came under
review of a panel of outside advisors to the FDA in March 2000.
At
the time, PIP said it had already sold 35,000 of its pre-filled saline
implants in the United States, and that it was the third-largest
manufacturer of breast implants in the world. It said it only had
reports of 521 complaints with its devices, a rate of 1.5 percent.
But
the panel recommended that the FDA reject PIP's application. It
recommended the implants from the other two companies, Inamed Inc, now
part of Allergan Inc and Mentor, now a unit of Johnson & Johnson.
Panelists
said at the time they were not reassured by PIP's data, and that the
company's clinical trials did not include enough patients that were
followed for an adequate time to truly evaluate the device's risks.
"Ill prepared"
One
panel member, Boyd Burkhardt, a plastic surgeon from Arizona, said the
company's data was incomplete, and he found it difficult to understand
why the company was "as ill prepared as you appear to be" to meet
regulatory standards.
"Like it or
not, we have a regulatory threshold which is probably higher or at least
different than it is elsewhere in the world, and I think in order to
get your product approved, you're just going to have to bite your tongue
and meet that threshold," Burkhardt told the company, according to a
transcript from the panel's meeting available on the FDA's website.
Asked
to comment on the PIP controversy, Burkhardt, in a brief interview,
said that he stands by the prior comments he made to the FDA.
It wasn't immediately clear why after the rejection the FDA then carried out an inspection of the PIP plant in May 2000.
PIP said it stopped selling its saline implants in the United States that same month, according to an SEC filing.

No comments:
Post a Comment